These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 34029516)

  • 21. Psoriasis care during the time of COVID-19: real-world data on changes in treatments and appointments from a German university hospital.
    Ninosu N; Roehrich F; Diehl K; Peitsch WK; Schaarschmidt ML
    Eur J Dermatol; 2021 Apr; 31(2):183-191. PubMed ID: 33871361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016.
    Carretero Hernández G; Ferrándiz C; Rivera Díaz R; Daudén Tello E; de la Cueva-Dobao P; Gómez-García FJ; Herrera-Ceballos E; Belinchón Romero I; López-Estebaranz JL; Alsina Gibert M; Sánchez-Carazo JL; Ferrán Farrés M; González Quesada A; Carrascosa Carrillo JM; Llamas-Velasco M; Mendiola Fernández MV; Ruiz Genao D; Muñoz Santos C; García-Doval I; Descalzo MA;
    Actas Dermosifiliogr (Engl Ed); 2018 Sep; 109(7):617-623. PubMed ID: 29887167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue.
    Takamura S; Sugai S; Taguchi R; Teraki Y
    J Dermatol; 2020 Mar; 47(3):290-294. PubMed ID: 31867729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acrodermatitis Continua of Hallopeau Evolving into Generalized Pustular Psoriasis Following COVID-19: A Case Report of a Successful Treatment with Infliximab in Combination with Acitretin.
    Samotij D; Gawron E; Szczęch J; Ostańska E; Reich A
    Biologics; 2021; 15():107-113. PubMed ID: 33948082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis.
    Sawyer LM; Wonderling D; Jackson K; Murphy R; Samarasekera EJ; Smith CH
    Pharmacoeconomics; 2015 Feb; 33(2):163-77. PubMed ID: 25526841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan.
    Kishimoto M; Komine M; Kamiya K; Sugai J; Mieno M; Ohtsuki M
    J Dermatol; 2020 Jan; 47(1):33-40. PubMed ID: 31696543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biologic therapy in erythrodermic and pustular psoriasis.
    Levin EC; Debbaneh M; Koo J; Liao W
    J Drugs Dermatol; 2014 Mar; 13(3):342-54. PubMed ID: 24595581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of Reactivation of Hepatitis B Virus Infection in Psoriasis Patients Treated With Biologics: A Retrospective Analysis of 20 Cases From the BIOBADADERM Database.
    Sanz-Bueno J; Vanaclocha F; García-Doval I; Torrado R; Carretero G; Daudén E; Patricia Ruiz-Genao D; Alsina-Gibert MM; Pérez-Zafrilla B; Pérez-Rial G; Rivera R;
    Actas Dermosifiliogr; 2015; 106(6):477-82. PubMed ID: 25776200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Val50Met hereditary transthyretin amyloidosis: not just a medical problem, but a psychosocial burden.
    González-Moreno J; Gaya-Barroso A; Losada-López I; Rodríguez A; Bosch-Rovira T; Ripoll-Vera T; Usón M; Figuerola A; Descals C; Montalà C; Ferrer-Nadal MA; Cisneros-Barroso E
    Orphanet J Rare Dis; 2021 Jun; 16(1):266. PubMed ID: 34112225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biologics for Psoriasis during the COVID-19 Pandemic.
    Kamiya K; Komine M; Ohtsuki M
    J Clin Med; 2021 Mar; 10(7):. PubMed ID: 33808455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The journey of adult psoriasis patients towards biologics: past and present - Results from the BioCAPTURE registry.
    van den Reek JMPA; Seyger MMB; van Lümig PPM; Driessen RJB; Schalkwijk CJM; Berends MAM; van de Kerkhof PCM; de Jong EMGJ
    J Eur Acad Dermatol Venereol; 2018 Apr; 32(4):615-623. PubMed ID: 29121430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of the COVID-19 pandemic on children with psoriasis.
    Beytout Q; Pepiot J; Maruani A; Devulder D; Aubert R; Beylot-Barry M; Amici JM; Jullien D; Mahé E; ; ;
    Ann Dermatol Venereol; 2021 Jun; 148(2):106-111. PubMed ID: 33637347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study.
    Georgakopoulos JR; Mufti A; Vender R; Yeung J
    J Am Acad Dermatol; 2020 Oct; 83(4):1212-1214. PubMed ID: 32679279
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy and cost of etanercept in long-term psoriasis: Rational use in clinical practice.
    Ruiz-Villaverde R; Galán-Gutierrez M; Barabash-Neila R; Rodriguez-Fernandez-Freire L; Conejo-Mir J
    J Dermatolog Treat; 2016; 27(1):37-42. PubMed ID: 26084590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of satisfaction degree of patients treated at the Inflammatory Bowel Disease Unit (IBDU) of Hospital Universitario 12 de Octubre between previous face-to-face care and telephone care during the COVID-19 pandemic.
    Vázquez García P; Fernández-Gordón Sánchez FM; Algara San Nicolás M; Yela San Bernardino C; Casis Herce B; Masedo González Á; Gómez Gómez GJ; Martínez Montiel MDP
    Rev Esp Enferm Dig; 2022 Jan; 114(1):58-59. PubMed ID: 34517711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combining systemic retinoids with biologic agents for moderate to severe psoriasis.
    Smith EC; Riddle C; Menter MA; Lebwohl M
    Int J Dermatol; 2008 May; 47(5):514-8. PubMed ID: 18412874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From biologic to biologic to biologic: lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis.
    Yip L; Harrison S; Foley P
    Australas J Dermatol; 2008 Aug; 49(3):152-5. PubMed ID: 18638223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing the Risk and Outcome of COVID-19 in Patients with Psoriasis or Psoriatic Arthritis on Biologic Treatment: A Critical Appraisal of the Quality of the Published Evidence.
    Piaserico S; Gisondi P; Cazzaniga S; Di Leo S; Naldi L
    J Invest Dermatol; 2022 Feb; 142(2):355-363.e7. PubMed ID: 34363826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should patients stop their biologic treatment during the COVID-19 pandemic.
    Bashyam AM; Feldman SR
    J Dermatolog Treat; 2020 Jun; 31(4):317-318. PubMed ID: 32191143
    [No Abstract]   [Full Text] [Related]  

  • 40. The risk of post-operative complications in psoriasis and psoriatic arthritis patients on biologic therapy undergoing surgical procedures.
    Bakkour W; Purssell H; Chinoy H; Griffiths CE; Warren RB
    J Eur Acad Dermatol Venereol; 2016 Jan; 30(1):86-91. PubMed ID: 25732669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.